Physician profile
Jody Carr
NPI 1881882264
$1,677.39
in general payments reported to CMS, 2019-2025
31 companies · $19.66 in 2025
The $19.66 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,328 · 2022: $288 · 2023: $42.28 · 2025: $19.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $314.08 | 2021-2022 | |
| Glaxosmithkline, LLC. | $220.27 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $122.17 | 2021 | |
| Janssen Biotech, INC. | $115.09 | 2021-2025 | Darzalex, Imbruvica, Talvey |
| Eisai INC. | $82.37 | 2021 | |
| Astellas Pharma US INC | $81.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.67 | 2021 | |
| Merck Sharp & Dohme LLC | $65.34 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $54.84 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $47.93 | 2021-2022 | |
| Incyte Corporation | $40.90 | 2021 | |
| Daiichi Sankyo INC. | $38.18 | 2021 | |
| Csl Behring | $34.02 | 2021 | |
| Emd Serono, INC. | $33.56 | 2021-2023 | Bavencio |
| Amag Pharmaceuticals, INC. | $31.15 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $30.89 | 2021 | |
| Novocure INC. | $25.62 | 2021 | |
| Acceleron Pharma, INC. | $24.99 | 2021 | |
| Foundation Medicine, INC. | $24.88 | 2021 | |
| Kite Pharma, INC. | $24.82 | 2021 | |
| Abbvie INC. | $24.13 | 2021 | |
| Pfizer INC. | $23.35 | 2021 | |
| Myriad Genetic Laboratories, INC. | $22.49 | 2021 | |
| Seagen INC. | $18.73 | 2021 | |
| Genentech USA, INC. | $17.28 | 2021 | |
| Celgene Corporation | $15.68 | 2021 | |
| Dova Pharmaceuticals | $15.37 | 2021 | |
| Karyopharm Therapeutics INC. | $15.25 | 2021 | |
| Acrotech Biopharma INC. | $15.11 | 2021 | |
| Lilly USA, LLC | $14.65 | 2021 | |
| Tersera Therapeutics LLC | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.